TICKERNERD
Menu
GTBPGTBPHealthcare · Biotechnology

GTBP Stock Forecast: GT Biopharma, Inc. Price Predictions for 2026-2027

Last close, 18 Sept 2026
$7.16

The 1 Wall Street analysts covering GT Biopharma, Inc. hold a median 12-month price target of $75 — +947.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 16 of 100 as at 19 Sept 2026 — in the weakest quartile. The Street sees upside; the factor read is a caution. That gap is the story on this page.

Market cap
$12.9M
Ticker Nerd rank
16 / 100
Median analyst target
$75
Analysts covering
1
Revenue$0.0
Operating income−$2.8M
Net income−$2.8M
Free cash flow−$2.5M
Quarterly, 7 quarters to 31 Mar 2026 · latest quarter's figure shown
Ticker Nerd rank

GTBP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores GT Biopharma, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 19 Sept 2026
16 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
91
Accruals
61
Volatility
43
Growth
40
Revisions
31
Issuance
24
Momentum
12
Value
11
Quality
8

Size (91): Smaller than most of the companies we track.

Quality (8): Profits are thin or unreliable for the size of the business, or they are not turning into cash.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

GTBP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on GTBP, reported as data — targets and ratings, the market's view beside the model's.

We don’t hold enough price history for this company yet.

What Wall Street says1 analysts
1 Buy0 Hold0 Sell
Low $75Median $75High $75

The green dot is the last close — the median target sits +947.5% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
2 Dec 2024Roth MKMInitiatesBuy$11
8 Aug 2023HC Wainwright & Co.ReiteratesBuy$5.00
7 Aug 2023EF HuttonReiteratesHold$2.00
5 June 2023HC Wainwright & Co.ReiteratesBuy$5.00
17 May 2023HC Wainwright & Co.ReiteratesBuy$5.00
16 May 2023EF HuttonReiteratesHold$2.00
3 Apr 2023HC Wainwright & Co.ReiteratesBuy$5.00
31 Mar 2023EF HuttonReiteratesHold$2.00
5 Jan 2023EF HuttonInitiatesHold$2.00
13 Sept 2022HC Wainwright & Co.MaintainsBuy$25 → $5.00
24 May 2021HC Wainwright & Co.InitiatesBuy$25
13 Apr 2021B. Riley FBRInitiatesBuy—
13 Apr 2021B. Riley SecuritiesInitiatesBuy—
17 Mar 2021Roth CapitalInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. GTBP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

GTBP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

GT Biopharma, Inc. (GTBP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
0.1×

Cheaper than 73% of US stocks

Price / sales
—
Price / book
3.6×

Cheaper than 28% of US stocks

EV / EBITDA
−10.9×

Cheaper than 85% of US stocks

Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
0.0%

Higher than 32% of US stocks

Net margin
0.0%

Higher than 30% of US stocks

Returns & dividend
Return on equity
−113.5%

Higher than 12% of US stocks

Return on assets
−158.2%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

GT Biopharma, Inc. (GTBP) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • GT Biopharma, Inc. has a market value of $12.9M and an enterprise value of $8.0M.

  • Revenue in the twelve months to 31 Mar 2026: $0.0.

  • Net income over the same four quarters: −$47.7M.

  • Free cash flow in the twelve months to 31 Mar 2026: −$13.2M.

  • Shares outstanding: 1.8M.

  • Trailing P/E: 0.1×; forward P/E: −0.7× — the forward figure prices analyst consensus estimates, not reported earnings.

  • GT Biopharma, Inc. employs 1 people.

Statement figures: company filings via Twelve Data, four quarters to 31 Mar 2026 · market figures as at 20 Sept 2026

Data provided by Twelve Data

Peers

GTBP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
GTBPGT Biopharma, Inc.$12.9M
16
ADILAdial Pharmaceuticals, Inc.$12.8M
21
CALCCalciMedica, Inc.$13.1M
27
PLURPluri, Inc.$13.3M
15
INTSIntensity Therapeutics, Inc.$13.4M
23
ENLVEnlivex Ltd.$13.6M
41
BIVIBioVie, Inc.$13.6M
25

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own GT Biopharma, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest GTBP news & analysis

GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma

GlobeNewsWire · 15 Sept 2026positive

GT Biopharma announced that the FDA cleared a new investigational new drug (IND) application for GTB-5550, a B7-H3-targeted natural killer (NK) cell engager, for use in multiple myeloma under an investigator sponsored trial protocol. The company also noted its Phase 1 basket trial in solid tumor patients is actively enrolling, and its unaudited cash balance of about $11 million is expected to fund operations into Q3 2027.

Why it matters — This expands GTB-5550's potential into a new indication, multiple myeloma, adding to the GTBP pipeline and extending its cash runway into Q3 2027.

GT Biopharma, Inc. (GTBP) Discusses TriKE Platform, Clinical Progress, and the Case for NK Cell Immunotherapy Transcript

Seeking Alpha · 11 Sept 2026neutral

GT Biopharma, Inc. (GTBP) discussed its TriKE platform, clinical progress, and the case for natural killer (NK) cell immunotherapy in a Seeking Alpha transcript. The item covers the company's pipeline and scientific positioning rather than announcing specific results.

Why it matters — A GTBP watcher would care because it offers insight into the company's NK cell immunotherapy platform and ongoing clinical developments directly from management.

GT Biopharma to Host Live Company Presentation on the Development of TriKE® Platform for Cancer Treatment, September 11, 2026

GlobeNewsWire · 11 Sept 2026neutral

GT Biopharma will host a live company presentation on September 11, 2026, at 2:00 p.m. Eastern Time, focused on the development of its TriKE® natural killer cell engager platform for cancer treatment.

Why it matters — GTBP watchers would care because the presentation offers a direct update on the company's proprietary TriKE® platform, a core focus of its clinical-stage immuno-oncology work.

GT Biopharma Reports Second Quarter 2026 Financial Results

GlobeNewsWire · 14 Aug 2026neutral

GT Biopharma reported its second quarter 2026 financial results. The Phase 1 trial of GTB-3650 TriKE remains ongoing, with an update anticipated in the second half of 2026.

Why it matters — The update indicates progress in the ongoing Phase 1 trial of GTB-3650, a key pipeline candidate for GTBP watchers to follow.

FAQ

Frequently asked questions about GTBP stock

What is the GTBP stock price forecast for 2026-2027?

The 1 Wall Street analysts covering GT Biopharma, Inc. have a median 12-month price target of $75, with estimates ranging from $75 to $75. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is GTBP stock a buy right now?

Of the 1 analysts covering GT Biopharma, Inc., 1 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks GT Biopharma, Inc. 16 out of 100 across roughly 4,600 US stocks as at 19 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank GTBP?

As at 19 Sept 2026, GT Biopharma, Inc. ranks 16 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (91 of 100).

Will GTBP stock go up?

No one can know that. What the data says: the median 12-month target from 1 analysts implies +947.5% from the last close, and Ticker Nerd's factor model ranks GT Biopharma, Inc. 16 out of 100 as at 19 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the GTBP stock forecast for 2030?

No analyst covering GT Biopharma, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GTBP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $75 to $75 over the next 12 months.

What does GT Biopharma, Inc. do?

GT Biopharma Inc. is a clinical-stage biopharmaceutical company focused on immuno-oncology therapies built around its proprietary TriKE platform.

What is the latest news on GTBP?

The most recent item we track (GlobeNewsWire, 15 Sept 2026): "GT Biopharma Announces Potential New Indication for GTB-5550, a B7-H3-Targeted Natural Killer (NK) Cell Engager, for Multiple Myeloma". GT Biopharma announced that the FDA cleared a new investigational new drug (IND) application for GTB-5550, a B7-H3-targeted natural killer (NK) cell engager, for use in multiple myeloma under an investigator sponsored trial protocol. The company also noted its Phase 1 basket trial in solid tumor patients is actively enrolling, and its unaudited cash balance of about $11 million is expected to fund operations into Q3 2027.

Company

About GT Biopharma, Inc.

GT Biopharma Inc. is a clinical-stage biopharmaceutical company focused on immuno-oncology therapies built around its proprietary TriKE platform. The company develops NK cell engager-based candidates designed to help natural killer cells recognize and attack cancer cells, supporting research in hematologic malignancies, solid tumors, and autoimmune conditions. Its current pipeline includes programs such as GTB-3650, GTB-5550, and GTB-7550, which reflect the company’s emphasis on targeted biologic therapies that work through immune cell engagement rather than traditional chemotherapy approaches. GT Biopharma’s work is centered on advancing novel cancer and immune-modulating treatments through product development, clinical research, and commercialization efforts in the biotechnology market.

CEO Mr. Michael Martin Breen L.L.B. · 1 employees · United States · https://www.gtbiopharma.com